Lonza has embarked on a $290 million expansion project to build a new biologics manufacturing plant; and critical containment equipment in the dispensary and sampling areas is to be supplied
Biopharmaceuticals take Extract Technology to Singapore.
Extract Technology has been awarded a contract from engineering contractor Bovis Lend Lease Pharmaceutical in Singapore.
Extract Technology had successfully installed equipment at Lonza's existing biopharmaceutical manufacturing plant site in Portsmouth, New Hampshire, USA, and the new Singapore site was initially designed to be a replica facility.
Extract will be supplying three of its world-renowned dispensing booths, one sampling booth and two dispensing benches, an almost identical installation to that in New Hampshire, with all of the equipment offering maximum protection to both the product and the operator through the precise control of airflow and the capture of micro-fine dust particles.
"We are pleased to be working with Lonza again in their continued expansion," says Mike Davies of Extract Technology.
"Apart from a few minor adjustments, we will be replicating the installation that has proved so successful in the USA.
The building is up now and we will be shipping equipment out to Singapore in November for installation and commissioning early in 2008".
The Singapore facility is Lonza's second in the country and will be a large-scale commercial mammalian cell culture manufacturing plant.
It intend to strengthen its leading position as the global custom manufacturer of biopharmaceuticals entering the fast growing Asian market.
Extract Technology manufactures downflow booths, isolators and pack-off systems for the pharmaceutical industry.
